Evidence map›Paper›PMID 37693076›Full record

ReviewBioinformation2022

CRISPR-Cas9 gene editing and human diseases.

Chaitra Jinka, Chithirala Sainath, Shyamaladevi Babu, Ashok Chakravarthi Chennupati, Lakshmi Prasanna Muppidi, Madhan Krishnan, Gayathri Sekar, Mayilvanan Chinnaiyan, Swapna Kumari Andugula

Open access · hybridAbstract readReview
In one paragraph

Review in Bioinformation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Chaitra JinkaDepartment of Animal Biotechnology, Sri Venkateswara University, Tirupati - 517502.
Chithirala SainathDepartment of Zoology, Sri Venkateswara University, Tirupati- 517502.
Shyamaladevi BabuFaculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India.
Ashok Chakravarthi ChennupatiDepartment of Physiotherapy, KIMS College of Physiotherapy, KIMS and RF, Amalapuram, Andhra Pradesh.
Lakshmi Prasanna MuppidiDepartment ofObstetrics and Gynecological Nursing, KIMS College Of Nursing, KIMS and RF, Amalapuram.
Madhan KrishnanFaculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India.
Gayathri SekarDepartment of pathology, Biosciences research Foundation, Chennai, Tamilnadu, India.
Mayilvanan ChinnaiyanDepartment of Otolaryngology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Swapna Kumari AndugulaKIMS College of Nursing, KIMS and RF, Amalapuram, East Godavari district, Andhra Pradesh, India.
Syngene International (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CRISPR/Cas-9 mediated genome editing has recently emerged as a potential and innovative technology in therapeutic development and biomedical research. Several recent studies have been performed to understand gene modification techniques in obtaining effective ex vivo results. Generally, the disease targets for gene correction will be in specific organs, so understanding the complete potential of genomic treatment methods is essential. From such a perspective, the present review revealed the significant importance of the CRISPR/ Cas9 delivery system. Both the promising gene-editing delivery systems, such as synthetic (non-viral) and viral vector systems are discussed in this review. In addition, this paper attempted to summarize the tissue-specific and organ-specific mRNA delivery systems that provide possible research information for future researchers. Further, the major challenges of the CRISPR/Cas9 system, such as off-target delivery, immunogenicity, and limited packaging, were also elucidated. Accordingly, this review illustrated a wide range of clinical applications associated with the efficient delivery of CRISPR/ Cas9 gene-editing. Moreover, this article emphasizes the role of the CRISPR/Cas9 system in treating Intra Cerebral haemorrhage (ICH), thereby suggesting future researchers to adopt more clinical trials on this breakthrough delivery system.

Indexed as

CRISPR-Cas9gene editingICHon-viral vector systemvviral vector system

Identifiers

PMID37693076
PMCPMC10484690
OpenAlexW4320031016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.